{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:19:54Z","timestamp":1792793994675,"version":"4.5.0"},"reference-count":104,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:p>The complement system is a tightly regulated, cascading protein network representing a key component linking the innate and humoral immune systems. However, if misdirected or dysregulated, it can be similarly damaging to host-tissue. The role of complement dysregulation on vascular endothelial cells has been well established in atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA) characterized by microangiopathic hemolytic anemia, thrombocytopenia, and target organ injury. Yet, a great deal of complexity exists around the role of complement in TMA associated with other diseases. A further complicating factor is the cross-talk between complement, neutrophils, and coagulation pathways in the pathophysiology of TMA. Advancements in the understanding of the etiopathogenesis of aHUS paved the way for the successful development of anticomplement therapies (complement C5 inhibitors), which have revolutionized the treatment of aHUS. Therefore, a clearer understanding of the role of the complement system in TMA associated with other conditions will help to identify patients who would benefit from these therapies. This review aims to provide an assessment of the nature and extent of complement involvement in TMA associated with autoimmune diseases such as systemic lupus erythematosus, antiphospholipid syndrome, and scleroderma renal crisis. Defining the role of complement in TMA in these conditions will help to guide timely diagnosis and management.<\/jats:p>","DOI":"10.3899\/jrheum.220752","type":"journal-article","created":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T13:25:16Z","timestamp":1673789116000},"page":"730-740","source":"Crossref","is-referenced-by-count":37,"title":["The Role of Complement in Autoimmune Disease-Associated Thrombotic Microangiopathy and the Potential for Therapeutics"],"prefix":"10.3899","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0433-238X","authenticated-orcid":false,"given":"Anuja","family":"Java","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4074-0516","authenticated-orcid":false,"given":"Alfred H.J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2023,1,15]]},"reference":[{"key":"2023060503351752000_50.6.730.1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in thrombotic microangiopathies: unraveling Ariadne\u2019s thread into the labyrinth of complement therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front Immunol"},{"key":"2023060503351752000_50.6.730.2","unstructured":"Java A. Chapter 10 \u2013 Thrombotic microangiopathy. In: Current Progress in Nephrology, 3rd Edition. Mumbai: TreeLife Media; 2022:181-96."},{"key":"2023060503351752000_50.6.730.3","first-page":"2","article-title":"Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis","volume":"14","author":"Laurence","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"2023060503351752000_50.6.730.4","unstructured":"Haller H. The role, use and pathophysiology of the complement system. Hot Topics in Nephrology session presented at ERA-EDTA 2021. [Accessed August 2021.] Available from: https:\/\/era-apps.m-anage.com\/eraedta21\/en-GB\/pag\/presentation\/494219"},{"key":"2023060503351752000_50.6.730.5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fped.2014.00097","article-title":"Extra-renal manifestations of complement-mediated thrombotic microangiopathies","volume":"2","author":"Hofer","year":"2014","journal-title":"Front Pediatr"},{"key":"2023060503351752000_50.6.730.6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","article-title":"Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome","volume":"94","author":"Schaefer","year":"2018","journal-title":"Kidney Int"},{"key":"2023060503351752000_50.6.730.7","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11470918"},{"key":"2023060503351752000_50.6.730.8","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11830720"},{"key":"2023060503351752000_50.6.730.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1312353"},{"key":"2023060503351752000_50.6.730.10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023060503351752000_50.6.730.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-010-1034-0"},{"key":"2023060503351752000_50.6.730.12","doi-asserted-by":"publisher","DOI":"10.1385\/IR:33:2:103"},{"key":"2023060503351752000_50.6.730.13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12974-020-02024-8","article-title":"The good, the bad, and the opportunities of the complement system in neurodegenerative disease","volume":"17","author":"Schartz","year":"2020","journal-title":"J Neuroinflammation"},{"key":"2023060503351752000_50.6.730.14","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1923"},{"key":"2023060503351752000_50.6.730.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0031-6"},{"key":"2023060503351752000_50.6.730.16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1556\/EuJMI.2.2012.2.2","article-title":"The complement system: history, pathways, cascade and inhibitors","volume":"2","author":"Nesargikar","year":"2012","journal-title":"Eur J Microbiol Immunol (Bp)"},{"key":"2023060503351752000_50.6.730.17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.3.1305"},{"key":"2023060503351752000_50.6.730.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00641.x"},{"key":"2023060503351752000_50.6.730.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2013.08.001"},{"key":"2023060503351752000_50.6.730.20","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.373"},{"key":"2023060503351752000_50.6.730.21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-221549"},{"key":"2023060503351752000_50.6.730.22","doi-asserted-by":"crossref","first-page":"607211","DOI":"10.3389\/fimmu.2020.607211","article-title":"Factor H autoantibodies and complement-mediated diseases","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"2023060503351752000_50.6.730.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.10.005"},{"key":"2023060503351752000_50.6.730.24","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.kint.2019.01.043","article-title":"Secondary atypical hemolytic uremic syndromes in the era of complement blockade","volume":"95","author":"Praga","year":"2019","journal-title":"Kidney Int"},{"key":"2023060503351752000_50.6.730.25","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2023060503351752000_50.6.730.26","doi-asserted-by":"crossref","first-page":"775280","DOI":"10.3389\/fmed.2021.775280","article-title":"Clinicopathologic implications of complement genetic variants in kidney transplantation","volume":"8","author":"Ren","year":"2021","journal-title":"Front Med"},{"key":"2023060503351752000_50.6.730.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.04.003"},{"key":"2023060503351752000_50.6.730.28","doi-asserted-by":"crossref","first-page":"e140711","DOI":"10.1172\/jci.insight.140711","article-title":"The complement system in COVID-19: friend and foe?","volume":"5","author":"Java","year":"2020","journal-title":"JCI Insight"},{"key":"2023060503351752000_50.6.730.29","first-page":"e138999","article-title":"Neutrophil extracellular traps in COVID-19","volume":"5","author":"Zuo","year":"2020","journal-title":"JCI Insight"},{"key":"2023060503351752000_50.6.730.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.09.012"},{"key":"2023060503351752000_50.6.730.31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-283564"},{"key":"2023060503351752000_50.6.730.32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fimmu.2016.00137","article-title":"NETosing neutrophils activate complement both on their own NETs and bacteria via alternative and non-alternative pathways","volume":"7","author":"Yuen","year":"2016","journal-title":"Front Immunol"},{"key":"2023060503351752000_50.6.730.33","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/art.41460","article-title":"Anti-neutrophil extracellular trap antibodies and impaired neutrophil extracellular trap degradation in antiphospholipid syndrome","volume":"72","author":"Zuo","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2023060503351752000_50.6.730.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101661"},{"key":"2023060503351752000_50.6.730.35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102404"},{"key":"2023060503351752000_50.6.730.36","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fimmu.2019.00672","article-title":"Complement therapeutics in autoimmune disease","volume":"10","author":"Thurman","year":"2019","journal-title":"Front Immunol"},{"key":"2023060503351752000_50.6.730.37","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283546703"},{"key":"2023060503351752000_50.6.730.38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-020-01888-5","article-title":"A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy","volume":"21","author":"Wright","year":"2020","journal-title":"BMC Nephrol"},{"key":"2023060503351752000_50.6.730.39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/diseases9010003","article-title":"Thrombotic microangiopathy among hospitalized patients with systemic lupus erythematosus in the United States","volume":"9","author":"Pivovarova","year":"2020","journal-title":"Diseases"},{"key":"2023060503351752000_50.6.730.40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2023060503351752000_50.6.730.41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/1744666X.2020.1745063","article-title":"Revisiting the complement system in systemic lupus erythematosus","volume":"16","author":"Sharma","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"2023060503351752000_50.6.730.42","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2011.39"},{"key":"2023060503351752000_50.6.730.43","doi-asserted-by":"publisher","DOI":"10.1086\/518257"},{"key":"2023060503351752000_50.6.730.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.11.014"},{"key":"2023060503351752000_50.6.730.45","doi-asserted-by":"publisher","DOI":"10.1186\/ar4016"},{"key":"2023060503351752000_50.6.730.46","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-00984-1"},{"key":"2023060503351752000_50.6.730.47","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018019596"},{"key":"2023060503351752000_50.6.730.48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fimmu.2016.00036","article-title":"Early components of the complement classical activation pathway in human systemic autoimmune diseases","volume":"7","author":"Lintner","year":"2016","journal-title":"Front Immunol"},{"key":"2023060503351752000_50.6.730.49","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.4.1317"},{"key":"2023060503351752000_50.6.730.50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.5.3231"},{"key":"2023060503351752000_50.6.730.51","doi-asserted-by":"publisher","DOI":"10.1002\/art.21893"},{"key":"2023060503351752000_50.6.730.52","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1999.00772.x"},{"key":"2023060503351752000_50.6.730.53","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203041"},{"key":"2023060503351752000_50.6.730.54","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001180"},{"key":"2023060503351752000_50.6.730.55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100450"},{"key":"2023060503351752000_50.6.730.56","doi-asserted-by":"publisher","DOI":"10.1186\/ar4264"},{"key":"2023060503351752000_50.6.730.57","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80885-7"},{"key":"2023060503351752000_50.6.730.58","doi-asserted-by":"publisher","DOI":"10.1186\/ar4142"},{"key":"2023060503351752000_50.6.730.59","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jth.15082","article-title":"Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications","volume":"19","author":"Chaturvedi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2023060503351752000_50.6.730.60","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2541"},{"key":"2023060503351752000_50.6.730.61","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/art.39938","article-title":"In vivo role of neutrophil extracellular traps in antiphospholipid antibody-mediated venous thrombosis","volume":"69","author":"Meng","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023060503351752000_50.6.730.62","doi-asserted-by":"publisher","DOI":"10.1002\/art.20433"},{"key":"2023060503351752000_50.6.730.63","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu394oa"},{"key":"2023060503351752000_50.6.730.64","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204838"},{"key":"2023060503351752000_50.6.730.65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1319"},{"key":"2023060503351752000_50.6.730.66","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.090670"},{"key":"2023060503351752000_50.6.730.67","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-08-0554"},{"key":"2023060503351752000_50.6.730.68","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew040"},{"key":"2023060503351752000_50.6.730.69","doi-asserted-by":"publisher","DOI":"10.1002\/art.34440"},{"key":"2023060503351752000_50.6.730.70","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/0961203320917460","article-title":"Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature","volume":"29","author":"Skoczynska","year":"2020","journal-title":"Lupus"},{"key":"2023060503351752000_50.6.730.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103055"},{"key":"2023060503351752000_50.6.730.72","doi-asserted-by":"crossref","first-page":"e4459","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement activation and effect of eculizumab in scleroderma renal crisis","volume":"95","author":"Devresse","year":"2016","journal-title":"Medicine"},{"key":"2023060503351752000_50.6.730.73","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1590\/2175-8239-jbn-3807","article-title":"Complement activation in atypical hemolytic uremic syndrome and scleroderma renal crisis: a critical analysis of pathophysiology","volume":"40","author":"Zuckerman","year":"2018","journal-title":"J Bras Nefrol"},{"key":"2023060503351752000_50.6.730.74","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11926-015-0551-y","article-title":"Recent developments in the classification, evaluation, pathophysiology, and management of scleroderma renal crisis","volume":"18","author":"Ghossein","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"2023060503351752000_50.6.730.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.12.009"},{"key":"2023060503351752000_50.6.730.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2008.08.001"},{"key":"2023060503351752000_50.6.730.77","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s13075-016-1168-x","article-title":"Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis","volume":"18","author":"Okr\u00f3j","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2023060503351752000_50.6.730.78","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ackd.2019.11.002","article-title":"Complement and renal thrombotic microangiopathy associated with hypertension and scleroderma","volume":"27","author":"Zuckerman","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"key":"2023060503351752000_50.6.730.79","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao3089"},{"key":"2023060503351752000_50.6.730.80","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3390\/jcm9072136","article-title":"Neutrophil extracellular traps generation relates with early stage and vascular complications in systemic sclerosis","volume":"9","author":"Didier","year":"2020","journal-title":"J Clin Med"},{"key":"2023060503351752000_50.6.730.81","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ekir.2021.01.021","article-title":"Role of C5 inhibition in idiopathic inflammatory myopathies and scleroderma renal crisis-induced thrombotic microangiopathies","volume":"6","author":"Gouin","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023060503351752000_50.6.730.82","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ckj\/sfv101","article-title":"Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome","volume":"8","author":"Thomas","year":"2015","journal-title":"Clin Kidney J"},{"key":"2023060503351752000_50.6.730.83","doi-asserted-by":"crossref","first-page":"20543581211008707","DOI":"10.1177\/20543581211008707","article-title":"Making the correct diagnosis in thrombotic microangiopathy: a narrative review","volume":"8","author":"McFarlane","year":"2021","journal-title":"Can J Kidney Health Dis"},{"key":"2023060503351752000_50.6.730.84","doi-asserted-by":"crossref","first-page":"962702","DOI":"10.1155\/2012\/962702","article-title":"Complement diagnostics: concepts, indications, and practical guidelines","volume":"2012","author":"Nilsson","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2023060503351752000_50.6.730.85","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05830519"},{"key":"2023060503351752000_50.6.730.86","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/ijlh.13954","article-title":"Diagnosis and treatment of thrombotic microangiopathy","volume":"44","author":"Thompson","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"2023060503351752000_50.6.730.87","unstructured":"United States Food and Drug Administration . Eculizumab \u2013 Highlights of prescribing information. [Internet. Accessed December 28, 2022]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125166s434lbl.pdf."},{"key":"2023060503351752000_50.6.730.88","unstructured":"United States Food and Drug Administration . Ravulizumab \u2013 Highlights of prescribing information. [Internet. Accessed December 28, 2022]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761108s020lbl.pdf."},{"key":"2023060503351752000_50.6.730.89","unstructured":"European Medicines Agency . Eculizumab \u2013 Summary of product characteristics. [Internet Accessed December 28, 2022] Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/19966\/SPC\/soliris\/#gref."},{"key":"2023060503351752000_50.6.730.90","unstructured":"European Medicines Agency . Ravulizumab \u2013 Summary of product characteristics. [Internet Accessed December 28, 2022] Available from: https:\/\/www.medicines.org.uk\/emc\/product\/11945\/smpc#gref."},{"key":"2023060503351752000_50.6.730.91","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"2023060503351752000_50.6.730.92","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.kint.2019.08.005","article-title":"Anticomplement therapies in \u201csecondary thrombotic microangiopathies\u201d: ready for prime time?","volume":"96","author":"Radhakrishnan","year":"2019","journal-title":"Kidney Int"},{"key":"2023060503351752000_50.6.730.93","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.12.034"},{"key":"2023060503351752000_50.6.730.94","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.423"},{"key":"2023060503351752000_50.6.730.95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981"},{"key":"2023060503351752000_50.6.730.96","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2015.11.026"},{"key":"2023060503351752000_50.6.730.97","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ekir.2019.07.016","article-title":"Eculizumab safety: five-year experience from the global atypical hemolytic uremic syndrome registry","volume":"4","author":"Rondeau","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2023060503351752000_50.6.730.98","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.ekir.2021.03.884","article-title":"Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults","volume":"6","author":"Barbour","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023060503351752000_50.6.730.99","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"100","author":"Ariceta","year":"2021","journal-title":"Kidney Int"},{"key":"2023060503351752000_50.6.730.100","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ekir.2022.02.021","article-title":"The rational use of complement inhibitors in kidney diseases","volume":"7","author":"Fakhouri","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2023060503351752000_50.6.730.101","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ekir.2021.02.012","article-title":"C5 inhibition in secondary thrombotic microangiopathies: a yet unresolved question","volume":"6","author":"Werion","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023060503351752000_50.6.730.102","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/ckj\/sfx081","article-title":"Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea","volume":"10","author":"Brocklebank","year":"2017","journal-title":"Clin Kidney J"},{"key":"2023060503351752000_50.6.730.103","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00109-021-02102-1","article-title":"Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy","volume":"100","author":"Haydock","year":"2022","journal-title":"J Mol Med"},{"key":"2023060503351752000_50.6.730.104","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.ackd.2019.11.003","article-title":"Peri- and post-operative evaluation and management of atypical hemolytic uremic syndrome (aHUS) in kidney transplantation","volume":"27","author":"Java,","year":"2020","journal-title":"Adv Chronic Kidney Dis"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.220752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T10:38:34Z","timestamp":1685961514000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.220752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,15]]},"references-count":104,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,1]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.3899\/jrheum.220752"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.220752","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,15]]}}}